Doxycycline, Azithromycin and Vitamin C (DAV): A potent combination therapy for targeting mitochondria and eradicating cancer stem cells (CSCs)

Here, we devised a new strategy for eradicating cancer stem cells (CSCs), via a "synthetic-metabolic" approach, involving two FDA-approved antibiotics and a dietary vitamin supplement. This approach was designed to induce a "rho-zero-like" phenotype in cancer cells. This strategy...

Full description

Saved in:

Bibliographic Details
Published in:	Aging (Albany, NY.) Vol. 11; no. 8; p. 2202
Main Authors:	Fiorillo, Marco, Tóth, Fanni, Sotgia, Federica, Lisanti, Michael P
Format:	Journal Article
Language:	English
Published:	United States 19.04.2019
Subjects:	Anti-Bacterial Agents - pharmacology Ascorbic Acid - pharmacology Azithromycin - pharmacology Cell Proliferation - drug effects Cell Survival - drug effects Doxycycline - pharmacology Humans MCF-7 Cells Mitochondria - drug effects Mitochondria - metabolism Neoplastic Stem Cells - drug effects Neoplastic Stem Cells - metabolism Organelle Biogenesis combination therapy mitochondrial ATP depletion Azithromycin Doxycycline Vitamin C glycolysis
ISSN:	1945-4589, 1945-4589
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Here, we devised a new strategy for eradicating cancer stem cells (CSCs), via a "synthetic-metabolic" approach, involving two FDA-approved antibiotics and a dietary vitamin supplement. This approach was designed to induce a "rho-zero-like" phenotype in cancer cells. This strategy effectively results in the synergistic eradication of CSCs, using vanishingly small quantities of two antibiotics. The 2 metabolic targets are i) the large mitochondrial ribosome and ii) the small mitochondrial ribosome. Azithromycin inhibits the large mitochondrial ribosome as an off-target side-effect. In addition, Doxycycline inhibits the small mitochondrial ribosome as an off-target side-effect. Vitamin C acts as a mild pro-oxidant, which can produce free radicals and, as a consequence, induces mitochondrial biogenesis. Remarkably, treatment with a combination of Doxycycline (1 μM), Azithromycin (1 μM) plus Vitamin C (250 μM) very potently inhibited CSC propagation by >90%, using the MCF7 ER(+) breast cancer cell line as a model system. The strong inhibitory effects of this DAV triple combination therapy on mitochondrial oxygen consumption and ATP production were directly validated using metabolic flux analysis. Therefore, the induction of mitochondrial biogenesis due to mild oxidative stress, coupled with inhibition of mitochondrial protein translation, may be a new promising therapeutic anti-cancer strategy. Consistent with these assertions, Vitamin C is known to be highly concentrated within mitochondria, by a specific transporter, namely SVCT2, in a sodium-coupled manner. Also, the concentrations of antibiotics used here represent sub-antimicrobial levels of Doxycycline and Azithromycin, thereby avoiding the potential problems associated with antibiotic resistance. Finally, we also discuss possible implications for improving health-span and life-span, as Azithromycin is an anti-aging drug that behaves as a senolytic, which selectively kills and removes senescent fibroblasts.
AbstractList	Here, we devised a new strategy for eradicating cancer stem cells (CSCs), via a "synthetic-metabolic" approach, involving two FDA-approved antibiotics and a dietary vitamin supplement. This approach was designed to induce a "rho-zero-like" phenotype in cancer cells. This strategy effectively results in the synergistic eradication of CSCs, using vanishingly small quantities of two antibiotics. The 2 metabolic targets are i) the large mitochondrial ribosome and ii) the small mitochondrial ribosome. Azithromycin inhibits the large mitochondrial ribosome as an off-target side-effect. In addition, Doxycycline inhibits the small mitochondrial ribosome as an off-target side-effect. Vitamin C acts as a mild pro-oxidant, which can produce free radicals and, as a consequence, induces mitochondrial biogenesis. Remarkably, treatment with a combination of Doxycycline (1 μM), Azithromycin (1 μM) plus Vitamin C (250 μM) very potently inhibited CSC propagation by >90%, using the MCF7 ER(+) breast cancer cell line as a model system. The strong inhibitory effects of this DAV triple combination therapy on mitochondrial oxygen consumption and ATP production were directly validated using metabolic flux analysis. Therefore, the induction of mitochondrial biogenesis due to mild oxidative stress, coupled with inhibition of mitochondrial protein translation, may be a new promising therapeutic anti-cancer strategy. Consistent with these assertions, Vitamin C is known to be highly concentrated within mitochondria, by a specific transporter, namely SVCT2, in a sodium-coupled manner. Also, the concentrations of antibiotics used here represent sub-antimicrobial levels of Doxycycline and Azithromycin, thereby avoiding the potential problems associated with antibiotic resistance. Finally, we also discuss possible implications for improving health-span and life-span, as Azithromycin is an anti-aging drug that behaves as a senolytic, which selectively kills and removes senescent fibroblasts.Here, we devised a new strategy for eradicating cancer stem cells (CSCs), via a "synthetic-metabolic" approach, involving two FDA-approved antibiotics and a dietary vitamin supplement. This approach was designed to induce a "rho-zero-like" phenotype in cancer cells. This strategy effectively results in the synergistic eradication of CSCs, using vanishingly small quantities of two antibiotics. The 2 metabolic targets are i) the large mitochondrial ribosome and ii) the small mitochondrial ribosome. Azithromycin inhibits the large mitochondrial ribosome as an off-target side-effect. In addition, Doxycycline inhibits the small mitochondrial ribosome as an off-target side-effect. Vitamin C acts as a mild pro-oxidant, which can produce free radicals and, as a consequence, induces mitochondrial biogenesis. Remarkably, treatment with a combination of Doxycycline (1 μM), Azithromycin (1 μM) plus Vitamin C (250 μM) very potently inhibited CSC propagation by >90%, using the MCF7 ER(+) breast cancer cell line as a model system. The strong inhibitory effects of this DAV triple combination therapy on mitochondrial oxygen consumption and ATP production were directly validated using metabolic flux analysis. Therefore, the induction of mitochondrial biogenesis due to mild oxidative stress, coupled with inhibition of mitochondrial protein translation, may be a new promising therapeutic anti-cancer strategy. Consistent with these assertions, Vitamin C is known to be highly concentrated within mitochondria, by a specific transporter, namely SVCT2, in a sodium-coupled manner. Also, the concentrations of antibiotics used here represent sub-antimicrobial levels of Doxycycline and Azithromycin, thereby avoiding the potential problems associated with antibiotic resistance. Finally, we also discuss possible implications for improving health-span and life-span, as Azithromycin is an anti-aging drug that behaves as a senolytic, which selectively kills and removes senescent fibroblasts. Here, we devised a new strategy for eradicating cancer stem cells (CSCs), via a "synthetic-metabolic" approach, involving two FDA-approved antibiotics and a dietary vitamin supplement. This approach was designed to induce a "rho-zero-like" phenotype in cancer cells. This strategy effectively results in the synergistic eradication of CSCs, using vanishingly small quantities of two antibiotics. The 2 metabolic targets are i) the large mitochondrial ribosome and ii) the small mitochondrial ribosome. Azithromycin inhibits the large mitochondrial ribosome as an off-target side-effect. In addition, Doxycycline inhibits the small mitochondrial ribosome as an off-target side-effect. Vitamin C acts as a mild pro-oxidant, which can produce free radicals and, as a consequence, induces mitochondrial biogenesis. Remarkably, treatment with a combination of Doxycycline (1 μM), Azithromycin (1 μM) plus Vitamin C (250 μM) very potently inhibited CSC propagation by >90%, using the MCF7 ER(+) breast cancer cell line as a model system. The strong inhibitory effects of this DAV triple combination therapy on mitochondrial oxygen consumption and ATP production were directly validated using metabolic flux analysis. Therefore, the induction of mitochondrial biogenesis due to mild oxidative stress, coupled with inhibition of mitochondrial protein translation, may be a new promising therapeutic anti-cancer strategy. Consistent with these assertions, Vitamin C is known to be highly concentrated within mitochondria, by a specific transporter, namely SVCT2, in a sodium-coupled manner. Also, the concentrations of antibiotics used here represent sub-antimicrobial levels of Doxycycline and Azithromycin, thereby avoiding the potential problems associated with antibiotic resistance. Finally, we also discuss possible implications for improving health-span and life-span, as Azithromycin is an anti-aging drug that behaves as a senolytic, which selectively kills and removes senescent fibroblasts.
Author	Lisanti, Michael P Tóth, Fanni Fiorillo, Marco Sotgia, Federica
Author_xml	– sequence: 1 givenname: Marco surname: Fiorillo fullname: Fiorillo, Marco organization: The Department of Pharmacy, Health and Nutritional Sciences, The University of Calabria, Cosenza, Italy – sequence: 2 givenname: Fanni surname: Tóth fullname: Tóth, Fanni organization: Translational Medicine, School of Environment and Life Sciences, Biomedical Research Centre (BRC), University of Salford, Greater Manchester, M5 4WT, United Kingdom – sequence: 3 givenname: Federica surname: Sotgia fullname: Sotgia, Federica organization: Translational Medicine, School of Environment and Life Sciences, Biomedical Research Centre (BRC), University of Salford, Greater Manchester, M5 4WT, United Kingdom – sequence: 4 givenname: Michael P surname: Lisanti fullname: Lisanti, Michael P organization: Translational Medicine, School of Environment and Life Sciences, Biomedical Research Centre (BRC), University of Salford, Greater Manchester, M5 4WT, United Kingdom
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/31002656$$D View this record in MEDLINE/PubMed
BookMark	eNpNUEtLAzEYDFKxDz16lRxbsHWTbNJdb2XrCwoeLL2Wr9mvbaSb1CQF1z_hX3atCp5mhhmGYbqkZZ1FQi5ZMmKZEvwGNsZuRixheSJPSIflqRymMstb_3ibdEN4TRIlZarOSFuwJOFKqg75nLr3Wtd6Zyxe08mHiVvvqlobS8GWdGEiVA0vaH86WQxu6YTuXUQbqXbVyliIxlkat-hhX9O18zSC32BsJtHKRKe3zpbewLGsCZVGw9HUYDV6GiJWVONuF2i_eCnC4JycrmEX8OIXe2R-fzcvHoez54enYjIb6lSKOOQsH2cJQ76S4xK4WLMUUCueSz0WmAk5Rg680aCEEiCV1kJhVipc8RQ175H-T-3eu7cDhrisTPjeARbdISw5ZyyXXDY39cjVb_SwqrBc7r2pwNfLvw_5F0Ftdgc
CitedBy_id	crossref_primary_10_1111_fcp_12605 crossref_primary_10_1089_adt_2020_1019 crossref_primary_10_1080_01616412_2021_1975225 crossref_primary_10_3892_ol_2023_14146 crossref_primary_10_1111_dth_13810 crossref_primary_10_1038_s41388_021_01807_4 crossref_primary_10_1016_j_expneurol_2023_114574 crossref_primary_10_1016_j_leukres_2021_106523 crossref_primary_10_3390_antiox10121894 crossref_primary_10_3390_cancers15041192 crossref_primary_10_1016_j_bcp_2022_114966 crossref_primary_10_3390_molecules26061562 crossref_primary_10_1007_s00280_023_04567_y crossref_primary_10_1016_j_semcancer_2020_04_006 crossref_primary_10_1186_s13046_021_01831_y crossref_primary_10_3389_fphar_2024_1375993 crossref_primary_10_1007_s12013_022_01123_y crossref_primary_10_1016_j_bbadis_2020_166016 crossref_primary_10_3390_ijms22158019 crossref_primary_10_1016_j_mito_2024_101977 crossref_primary_10_1016_j_chembiol_2025_03_008 crossref_primary_10_1007_s12094_024_03553_x crossref_primary_10_1016_j_lfs_2023_122065 crossref_primary_10_1186_s13023_022_02331_8 crossref_primary_10_3390_cells9061529 crossref_primary_10_1080_09553002_2021_1976864 crossref_primary_10_1111_fcp_12900 crossref_primary_10_1016_j_cyto_2023_156285 crossref_primary_10_3390_ijms21228684 crossref_primary_10_1016_j_mito_2021_11_002 crossref_primary_10_3389_fonc_2021_740720 crossref_primary_10_3390_cancers14112608 crossref_primary_10_1371_journal_pgen_1010629 crossref_primary_10_3390_cancers17010059 crossref_primary_10_1007_s11033_022_07265_9 crossref_primary_10_1038_s41413_025_00411_6 crossref_primary_10_3390_biom11071050 crossref_primary_10_1016_j_semcancer_2019_07_022 crossref_primary_10_1186_s13046_021_02134_y crossref_primary_10_1016_j_freeradbiomed_2021_09_024 crossref_primary_10_4251_wjgo_v15_i3_443 crossref_primary_10_1007_s00011_024_01972_8 crossref_primary_10_1016_j_eurpolymj_2024_113267 crossref_primary_10_1177_03000605221093308 crossref_primary_10_1016_j_canlet_2020_10_036 crossref_primary_10_3390_ph13110409 crossref_primary_10_1155_2019_7286737 crossref_primary_10_2217_nnm_2022_0274 crossref_primary_10_3390_biom10010079 crossref_primary_10_1111_febs_15531 crossref_primary_10_1186_s43094_024_00637_x crossref_primary_10_1016_j_biopha_2020_110694 crossref_primary_10_1124_pharmrev_121_000300 crossref_primary_10_3390_cancers13153878
ContentType	Journal Article
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.18632/aging.101905
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine Biology
EISSN	1945-4589
ExternalDocumentID	31002656
Genre	Research Support, Non-U.S. Gov't Journal Article
GroupedDBID	--- 53G ADBBV ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL CGR CUY CVF DIK E3Z ECM EIF FRP GX1 HYE KQ8 M48 NPM O5R O5S OK1 PGMZT RPM W2D 7X8
ID	FETCH-LOGICAL-c453t-2197801e2b57da23f14aec6295c73e8357e2a2629a6363a56cc36e8d6eb24ec2
IEDL.DBID	7X8
ISICitedReferencesCount	68
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000466768900006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1945-4589
IngestDate	Sun Nov 09 11:26:43 EST 2025 Thu Jan 02 22:58:10 EST 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	false
IsScholarly	true
Issue	8
Keywords	combination therapy mitochondrial ATP depletion Azithromycin Doxycycline Vitamin C glycolysis
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c453t-2197801e2b57da23f14aec6295c73e8357e2a2629a6363a56cc36e8d6eb24ec2
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
OpenAccessLink	https://pubmed.ncbi.nlm.nih.gov/PMC6520007
PMID	31002656
PQID	2211952500
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_2211952500 pubmed_primary_31002656
PublicationCentury	2000
PublicationDate	20190419
PublicationDateYYYYMMDD	2019-04-19
PublicationDate_xml	– month: 4 year: 2019 text: 20190419 day: 19
PublicationDecade	2010
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Aging (Albany, NY.)
PublicationTitleAlternate	Aging (Albany NY)
PublicationYear	2019
SSID	ssj0065546
Score	2.4738762
Snippet	Here, we devised a new strategy for eradicating cancer stem cells (CSCs), via a "synthetic-metabolic" approach, involving two FDA-approved antibiotics and a...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	2202
SubjectTerms	Anti-Bacterial Agents - pharmacology Ascorbic Acid - pharmacology Azithromycin - pharmacology Cell Proliferation - drug effects Cell Survival - drug effects Doxycycline - pharmacology Humans MCF-7 Cells Mitochondria - drug effects Mitochondria - metabolism Neoplastic Stem Cells - drug effects Neoplastic Stem Cells - metabolism Organelle Biogenesis
Title	Doxycycline, Azithromycin and Vitamin C (DAV): A potent combination therapy for targeting mitochondria and eradicating cancer stem cells (CSCs)
URI	https://www.ncbi.nlm.nih.gov/pubmed/31002656 https://www.proquest.com/docview/2211952500
Volume	11
WOSCitedRecordID	wos000466768900006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bS8MwFA7qVHzxfr8QwQcFy9ZcW19kbA5fHIIieytZksIe1k47xfon_MuepJ0-CYIvpSVtSZPTk-_kS86H0JlImWA6jgNjGAQoQzYMhpLLQMPw52i0kKrIi03Ifj8aDOL7esKtqJdVznyid9Qm126OvElcKjLHwbWuJ8-BU41y7GotoTGPGhSgjLNqOfhmEQSvNupAnM4DxqO4zrEZCUqaXgPIxa5xi_-OLv0o01v7b_3W0WqNL3G7MogNNGezTbRUKU6Wm2j5rubSt9BnN38vdem2RtpL3P4YOcWEcQmFWGUGP42magznHXzebT9dXOE2nuQAsKcY6gPhtO9RXG3fKjFAX1wtKofvxWNwE-BWMwPW7V8GNxk_OQiF2tnZC3YJpLGjDQp83nnoFBfb6LF389i5DWp5hkAzTqcB-DoJ45slQy6NIjQNmbJakJhrSS0gO2mJInCtBBVUcaE1FTYyAoJ5ZjXZQQtZntk9hHXLCOd6RJhqlgJmShlEztLQlFOZcrGPTmdtnoD1u7qpzOavRfLT6vtot-q4ZFKl6UgcdUEArh784elDtAJIyNNEYXyEGin8-_YYLeq36ah4OfFmBcf-_d0X5jvW4A
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Doxycycline%2C+Azithromycin+and+Vitamin+C+%28DAV%29%3A+A+potent+combination+therapy+for+targeting+mitochondria+and+eradicating+cancer+stem+cells+%28CSCs%29&rft.jtitle=Aging+%28Albany%2C+NY.%29&rft.au=Fiorillo%2C+Marco&rft.au=T%C3%B3th%2C+Fanni&rft.au=Sotgia%2C+Federica&rft.au=Lisanti%2C+Michael+P&rft.date=2019-04-19&rft.issn=1945-4589&rft.eissn=1945-4589&rft.volume=11&rft.issue=8&rft.spage=2202&rft_id=info:doi/10.18632%2Faging.101905&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1945-4589&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1945-4589&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1945-4589&client=summon